Transition Therapeutics (TTHI) 6.67 $TTHI
22.3% Return Seen to Date on SmarTrend Transition Therapeutics Call (TTHI)
Comtex SmarTrend(R) - Thu Feb 12, 11:04AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 8 months, Transition Therapeutics has returned 22.31% as of today's recent price of $6.77.
TTHI: 6.67 (-0.07)
Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares
PR Newswire - Thu Feb 12, 7:00AM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) today announced the pricing of its underwritten public offering of 3,076,923 common shares at a price to the public of US$6.50 per share for total gross proceeds of US$20 million. The Company has granted the underwriters a 30-day option to purchase up to an additional 461,538 common shares, which could result in an additional US$3 million of gross proceeds. The offering is expected to close on February 18, 2015, subject to customary closing conditions. Cowen and Company, LLC is the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC are the co-managers for the offering.
TTH.TO: 8.30 (-0.05), TTHI: 6.67 (-0.07)
Transition Therapeutics initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:20PM CST
TTHI: 6.67 (-0.07)
Transition Therapeutics Inc. Announces Public Offering of Common Shares
PR Newswire - Wed Feb 11, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) announced today that it has commenced an underwritten public offering of its common shares. The Company expects to use net proceeds from the sale of the common shares for general corporate purposes, including expenditures related to the advancement of the Company's drug candidates through the various clinical trial phases.
TTH.TO: 8.30 (-0.05), TTHI: 6.67 (-0.07)
Transition Therapeutics' (TTHI) CEO Tony Cruz on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 5:54PM CST
TTHI: 6.67 (-0.07)
Transition Therapeutics reports FQ2 earnings
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:08PM CST
TTHI: 6.67 (-0.07)
Transition Therapeutics Announces Second Quarter Fiscal 2015 Financial Results
CNW Group - Mon Feb 09, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the three and six month periods ended December 31, 2014. Investors are invited to participate in a conference call today at 4:30pm EST to discuss these results. Dial in information for the call is as follows: (800) 381-7839 (North America) and (212) 231-2900 (International). A replay of the conference call will be available on the Company's website (www.transitiontherapeutics.com) for seven days following the call.
TTH.TO: 8.30 (-0.05), TTHI: 6.67 (-0.07)
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2015 Financial Results on Monday, February 9th, at 4:30 P.M. EST
CNW Group - Thu Feb 05, 11:00AM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Monday, February 9th, 2015 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2015 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (800) 381-7839 (North America), (212) 231-2900 (International). A replay of the conference call will be available on Transition's website www.transitiontherapeutics.com for seven days following the call.
TTH.TO: 8.30 (-0.05), TTHI: 6.67 (-0.07)
Transition Therapeutics Has Returned 25.9% Since SmarTrend Recommendation (TTHI)
Comtex SmarTrend(R) - Thu Feb 05, 9:42AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 8 months, Transition Therapeutics has returned 25.93% as of today's recent price of $6.97.
TTHI: 6.67 (-0.07)
Transition Therapeutics Shares Up 25.4% Since SmarTrend's Buy Recommendation (TTHI)
Comtex SmarTrend(R) - Thu Jan 29, 9:16AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 8 months, Transition Therapeutics has returned 25.38% as of today's recent price of $6.94.
TTHI: 6.67 (-0.07)
Transition Therapeutics Up 22.9% Since SmarTrend Uptrend Call (TTHI)
Comtex SmarTrend(R) - Wed Jan 14, 11:10AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 7 months, Transition Therapeutics has returned 22.85% as of today's recent price of $6.80.
TTHI: 6.67 (-0.07)
Shares of TTHI Up 23.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 31, 9:17AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 7 months, Transition Therapeutics has returned 23.58% as of today's recent price of $6.84.
TTHI: 6.67 (-0.07)
22.3% Return Seen to Date on SmarTrend Transition Therapeutics Call (TTHI)
Comtex SmarTrend(R) - Thu Feb 12, 11:04AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 8 months, Transition Therapeutics has returned 22.31% as of today's recent price of $6.77.
TTHI: 6.67 (-0.07)
Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares
PR Newswire - Thu Feb 12, 7:00AM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) today announced the pricing of its underwritten public offering of 3,076,923 common shares at a price to the public of US$6.50 per share for total gross proceeds of US$20 million. The Company has granted the underwriters a 30-day option to purchase up to an additional 461,538 common shares, which could result in an additional US$3 million of gross proceeds. The offering is expected to close on February 18, 2015, subject to customary closing conditions. Cowen and Company, LLC is the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC are the co-managers for the offering. TTH.TO: 8.30 (-0.05), TTHI: 6.67 (-0.07)
Transition Therapeutics initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:20PM CST
TTHI: 6.67 (-0.07)
Transition Therapeutics Inc. Announces Public Offering of Common Shares
PR Newswire - Wed Feb 11, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) announced today that it has commenced an underwritten public offering of its common shares. The Company expects to use net proceeds from the sale of the common shares for general corporate purposes, including expenditures related to the advancement of the Company's drug candidates through the various clinical trial phases. TTH.TO: 8.30 (-0.05), TTHI: 6.67 (-0.07)
Transition Therapeutics' (TTHI) CEO Tony Cruz on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 5:54PM CST
TTHI: 6.67 (-0.07)
Transition Therapeutics reports FQ2 earnings
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:08PM CST
TTHI: 6.67 (-0.07)
Transition Therapeutics Announces Second Quarter Fiscal 2015 Financial Results
CNW Group - Mon Feb 09, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the three and six month periods ended December 31, 2014. Investors are invited to participate in a conference call today at 4:30pm EST to discuss these results. Dial in information for the call is as follows: (800) 381-7839 (North America) and (212) 231-2900 (International). A replay of the conference call will be available on the Company's website (www.transitiontherapeutics.com) for seven days following the call. TTH.TO: 8.30 (-0.05), TTHI: 6.67 (-0.07)
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2015 Financial Results on Monday, February 9th, at 4:30 P.M. EST
CNW Group - Thu Feb 05, 11:00AM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) will hold a conference call on Monday, February 9th, 2015 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2015 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (800) 381-7839 (North America), (212) 231-2900 (International). A replay of the conference call will be available on Transition's website www.transitiontherapeutics.com for seven days following the call. TTH.TO: 8.30 (-0.05), TTHI: 6.67 (-0.07)
Transition Therapeutics Has Returned 25.9% Since SmarTrend Recommendation (TTHI)
Comtex SmarTrend(R) - Thu Feb 05, 9:42AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 8 months, Transition Therapeutics has returned 25.93% as of today's recent price of $6.97.
TTHI: 6.67 (-0.07)
Transition Therapeutics Shares Up 25.4% Since SmarTrend's Buy Recommendation (TTHI)
Comtex SmarTrend(R) - Thu Jan 29, 9:16AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 8 months, Transition Therapeutics has returned 25.38% as of today's recent price of $6.94.
TTHI: 6.67 (-0.07)
Transition Therapeutics Up 22.9% Since SmarTrend Uptrend Call (TTHI)
Comtex SmarTrend(R) - Wed Jan 14, 11:10AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 7 months, Transition Therapeutics has returned 22.85% as of today's recent price of $6.80.
TTHI: 6.67 (-0.07)
Shares of TTHI Up 23.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 31, 9:17AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 7 months, Transition Therapeutics has returned 23.58% as of today's recent price of $6.84.
TTHI: 6.67 (-0.07)
